AKT1 and diabetic kidney disease: Butyrate also ameliorated muscle atrophy in diabetic nephropathy by activating the free fatty acid 2 (FFA2)-regulated phosphatidylinositol 3-kinase (PI3K)/Protein Kinase B (Akt)/mTOR signaling pathway [22].